Plain-English translation of NCT06540443 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This pilot study is testing MPB-2043, a special contrast agent injected during an MRI scan to help doctors see lymph nodes more clearly. The medication uses tiny iron oxide particles that make it easier to tell the difference between healthy lymph nodes and ones affected by cancer. The trial will test four different doses of the medication to find which works best and when doctors should take the images after injection.
Detecting cancer in small lymph nodes is one of the biggest challenges in treating head and neck cancer. Standard MRI often misses these small cancerous nodes, which can lead to incomplete treatment. This trial aims to see if this new medication can help doctors spot these dangerous nodes earlier and more accurately.
You likely qualify if…
You likely don't qualify if…
You will receive the new contrast medication as an injection and then have MRI scans taken at different times afterward to see how well it helps visualize your lymph nodes. The study compares these enhanced images to regular MRI scans to determine which dose of medication works best. You will be followed to monitor for any side effects, and your safety will be carefully tracked throughout the study.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Taiwan